Pfizer CEO Bourla says company prepared if modified COVID vaccine required

  • Pfizer CEO Albert Bourla said that the pharma is prepared and has the manufacturing capacity to produce a new COVID-19 vaccine that addresses variants of concern.
  • Speaking on CNBC's "The Exchange," the exec said that the the company is developing a Omicron-specific vaccine and can produce a multivalent shot against multiple variants.
  • The U.S. FDA's Vaccines and Related Biological Products Advisory Committee is set to meet on June 28 to discuss if COVID-19 vaccines should be modified, and if so, what variant should be considered.
  • Bourla also addressed Pfizer 's (NYSE:PFE) recent Emergency Use Authorization (EUA) request for their COVID vaccine in children under the age of 5. He said the company would "pretty soon" submit data on three doses in this population.
  • Bourla noted he expects the 3-dose data to be similar to that seen in children above 5. That showed a 36 times higher immune response after the third shot compared to the second, he said.
  • In February, Pfizer (PFE) and partner BioNTech (BNTX) delayed the EUA application to await data on the 3-dose regimen.

    For this year Pfizer 's revenue will be around 60 billion USD. This is according to the average of the analysts' estimates. This is slightly more than 2022's revenue of 58.5 billion USD.

    Historical revenues and results Pfizer plus estimates 2023

    beurskoers

    Pfizer The Netherlands Rotterdam ©

    Pfizer
    Pfizer


    The analysts expect for 2023 a net profit of 12.59 billion USD. For this year the majority of the analysts, consulted by press agency Thomson Reuters, expects a profit per share of 2.2 USD. The price/earnings-ratio is then 12.57.

    Huge dividend Pfizer

    Analysts expect a dividend of 1.7 USD per share. Thus the dividend yield equals 6.15 percent. The average dividend yield of the pharmaceutical companies is a good 2.07 percent.

    Pfizer 's market capitalization is based on the number of outstanding shares around 155.34 billion USD.

    On Friday the stock closed at 27.66 USD.

    Historical stock prices Pfizer

    historical stocks pfizer

    ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
    news@valuespectrum.com

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.